Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diflunisal. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 7/20 | 1.00 |
| ▸ | TTR | P02766 | 2/20 | 1.00 |
| ▸ | DHFR | P00374 | 2/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | HMGB1 | P09429 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | CXCL12 | P48061 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 8/20 | 0.53 |
| ▸ | HNF4A | P41235 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diflunisal SCHEMBL29367380 | 1.00 | ACMSD (1.00) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL30509654 | 1.00 | ACMSD (1.00) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL3848363 | 1.00 | ACMSD (1.00) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL28916416 | 0.98 | ACMSD (0.97) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL11425421 | 0.98 | ACMSD (0.97) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL20876816 | 0.98 | ACMSD (0.97) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL1869144 | 0.98 | ACMSD (0.97) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL28338853 | 0.98 | ACMSD (0.97) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL28350701 | 0.95 | ACMSD (0.91) | ACMSDTTRDHFRCA1CA2 | |
| Diflunisal SCHEMBL6690010 | 0.94 | ACMSD (0.89) | ACMSDTTRDHFRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 58685 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137702-A1 | Salicylate Compound Composition | INNOVATE EU LTD (GB) | 2026-05-21 | — | — | US | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-20260130928-A1 | COMBINATION OF AKR1C3 ACTIVATED ANTICANCER PRODRUG COMPOUND AND ANALGESIC DRUG FOR TREATING CANCER PATIENTS ACCOMPANIED BY PAIN | ASCENTAWITS PHARMACEUTICALS LTD (CN) | 2026-05-14 | — | — | US | claimed |
| CN-122028914-A | Combination therapy for autoimmune disorders | 拜奥海芬治疗学有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | claimed |
| US-12605432-B2 | Combinations for antigen based therapy | DIAMYD MEDICAL AB (SE) | 2026-04-21 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12600696-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2026-04-14 | — | — | US | claimed |
| EP-0017102-A1 | Composition containing a phenyl benzoic acid compound and acetaminophen combination for the treatment of pain and inflammation and process for preparing the same | MERCK & CO. INC. (US) | 1980-10-15 | — | — | EP | claimed |
| US-4228161-A | INDOMETHACIN AND A SUBSTITUTED PHENYL BENZOIC ACID | MERCK & CO., INC. (US) | 1980-10-14 | — | — | US | claimed |
| US-4225730-A | Process for preparing 4-(2,4-difluorophenyl)-salicyclic acid | MERCK & CO., INC. (US) | 1980-09-30 | — | — | US | claimed |
| US-4217340-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 1980-08-12 | — | — | US | claimed |
| US-4216340-A | Preparation of 5-(2,4-difluorophenyl)salicylic acid and derivatives | MERCK & CO., INC. (US) | 1980-08-05 | — | — | US | claimed |
| EP-0009808-A1 | Composition having skeletal muscle relaxant activity | MERCK & CO. INC. (US) | 1980-04-16 | — | — | EP | claimed |
| US-4163783-A | ACID AND A BIS/2-PYRIDYL-1-OXIDE/DISULFIDE | KLEIN ROBERT W | 1979-08-07 | — | — | US | claimed |
| EP-0002834-A2 | Preparation of salicylic acid and derivatives | MERCK & CO. INC. (US) | 1979-07-11 | — | — | EP | claimed |
| US-4152430-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1979-05-01 | — | — | US | claimed |
| US-4131618-A | Preparation of salicylic acid and derivatives | MERCK & CO., INC. (US) | 1978-12-26 | — | — | US | claimed |